2025年1月28日 · Xolair (omalizumab) injection is used to reduce the risk of severe food allergy reactions (anaphylaxis) and help improve allergic asthma, nasal polyps, and chronic hives. …

Learn about XOLAIR®, a self-administered treatment for allergic asthma, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria, and food allergy. See full prescribing, safety, …

XOLAIR ® (omalizumab) for subcutaneous use is an injectable prescription medicine used to treat food allergy in people 1 year of age and older to reduce allergic reactions that may occur after …

XOLAIR ® (omalizumab) for subcutaneous use is an injectable prescription medicine used to treat moderate to severe persistent asthma in people 6 years of age and older whose asthma …

Determine dose (mg) and dosing frequency by serum total IgE level (IU/mL), measured before the start of treatment, and body weight (kg). See the dose determination charts. (2.1) Chronic...

2024年2月28日 · Xolair (omalizumab) is a monoclonal antibody indicated for adults and pediatric patients 6 years of age and older with a positive skin test or in vitro reactivity to a perennial …

2024年6月3日 · Divide doses of greater than 150 mg among at least 2 injection sites. Adjust dosing if patient weight significantly changes. May take 5 to 10 seconds to inject. Refrigerate, …

2010年11月17日 · Administer XOLAIR 75 mg to 600 mg by subcutaneous injection every 2 or 4 weeks. The patient's pretreatment serum total immunoglobulin E (IgE) level (IU/mL), and body …

2023年8月17日 · Omalizumab is an FDA-approved drug used for the treatment of moderate-to-severe persistent asthma in adults and pediatric patients 6 or older who have a positive skin …

Patients received omalizumab at 75 mg, 150 mg or 300 mg or placebo by subcutaneous injection every 4 weeks for 24 and 12 weeks in studies 1 and 2, respectively, and 300 mg or placebo by …